Clinical Trial

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2027-05 -> 2028-01 2026-03-31
minor Completion pushed: 2027-05 -> 2028-01 2026-03-31
Trial Details
NCT Number NCT06657144
Lead Sponsor Coherus Oncology, Inc.
Conditions Metastatic Solid Tumor, Advanced Solid Tumor
Enrollment 154 participants
Start Date 2025-04-01
Primary Completion 2028-01 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-15